FEATURED PRODUCT:
CollaRx® Gentamicin Topical
Infected Diabetic Foot Ulcers are a significant unmet medical need.
FACT: 10% of Western Society is diabetic.
FACT: 15% of diabetics in Western Societies develop foot ulcers.
FACT: 50% of diabetic foot ulcers become infected.
FACT: Every 30 seconds a diabetic foot is amputated.
With strong support from Key Opinion Leaders in the field, Innocoll is developing its CollaRx Gentamicin sponge for the topical application to treat and prevent infection in Diabetic foot ulcers.
"Topical therapy has many potential advantages, including high local antibiotic levels without systemic levels, limited total antibiotic usage and avoidance of systemic toxic effects. Preliminary data on collagen sponges and existing data on locally applied gentamicin suggest that this is a potentially beneficial method of treating diabetic foot infections."
Ben Lipsky MD - Professor of Medicine University of Washington
"It is therefore with great enthusiasm that I recently found out of Innocoll's intention to move forward with clinical trials of aminoglycoside-impregnated collagen sponges for treatment of diabetic foot infections."
David Armstrong DPM, PhD - Professor of Surgery, Director of Lower Extremity Research and the Southern Arizona Limb Salvage Alliance (SALSA), University of Arizona